SMITH & NEPHEW PLC Funds and ETFs Smith & Nephew Plc
Equities
SN.
GB0009223206
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,004 GBX | +0.30% |
|
+0.77% | -6.86% |
| 05-09 | Smith & Nephew plc Announces Final Dividend of the Year Ended 31 December 2023, Payable on May 22, 2024 | CI |
| 05-09 | SMITH & NEPHEW : Q1 24: A few positives underneath the top-line miss |  |
ETFs positioned on Smith & Nephew Plc
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | +3.63% | - | |
| 0.01% | 0 M€ | +0.50% | - | |
| 0.01% | 0 M€ | +0.32% | - | |
| 0.00% | 0 M€ | +2.72% | - | |
| 0.00% | 7 M€ | +0.11% | - | |
| 0.00% | 0 M€ | 0.00% | - | |
| 0.00% | 0 M€ | -2.25% | - | |
| 0.00% | 0 M€ | -2.58% | - | |
| 0.00% | 0 M€ | -3.22% | - |
Smith & Nephew Plc specializes in designing, manufacturing and marketing medical products and equipment. Net sales break down by activity sector as follows:
- orthopedic surgery (39.9%): primarily orthopedic implants (hips, knees and shoulders);
- sports medicine, arthroscopy and cervicofacial surgery (31.2%): surgery and damaged tissue repair products and instruments, visualization products, etc.;
- wound care (28.9%): skin grafts for major burns victims, treatments for leg ulcers, etc.
The United States accounts for 53.7% of net sales.
Calendar
24/07/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
12.57
USD
Average target price
16.35
USD
Spread / Average Target
+30.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.86% | 10.96B | |
| +10.39% | 126B | |
| +2.52% | 8.97B | |
| +38.96% | 5.56B | |
| -17.50% | 4.99B | |
| +8.36% | 3.44B | |
| -8.84% | 2.8B | |
| -7.52% | 2.18B | |
| -3.00% | 2.16B | |
| -21.88% | 1.82B |
- Stock Market
- Equities
- SN. Stock
- Funds and ETFs Smith & Nephew Plc
